Recombinant ErbB2/Her2 (Trastuzumab Biosimilar) anticorps
Reactivité: Humain
FACS, ELISA, IHC
Hôte: Human
Monoclonal
4D5-8
unconjugated
Recombinant Antibody
(1 reference)-
- Antigène Tous les produits ErbB2/Her2 (Trastuzumab Biosimilar)
- ErbB2/Her2 (Trastuzumab Biosimilar)
- Type d'anticorp
- Recombinant Antibody
- Reactivité
- Humain
-
Hôte
-
Human
-
Clonalité
- Monoclonal
-
Conjugué
- Cet anticorp ErbB2/Her2 (Trastuzumab Biosimilar) est non-conjugé
-
Application
- Flow Cytometry (FACS), ELISA, Immunohistochemistry (IHC)
- Specificité
- Oncogenic protein Her-2/neu (erbB-2), a member of the family of epidermal growth factor (EGF) receptors, overexpressed in 30 % of invasive breast cancers and 70 % of ductal carcinomata in situ, in a small percentage of melanomas, and in other malignancies originating from various organs, including ovary, kidney, colon, and bladder.
- Attributs du produit
-
OriginalSpeciesName: Human
OriginalFormat: IgG1
- Purification
- Purified antibody.
- Pureté
- > 98 % as determined by SDS-PAGE
- niveau d'endotoxine
- Endotoxin is < 1.0 EU/mg as determined by the LAL method
- Immunogène
- A431 cells (human epidermoid carcinoma) (over)expressing EGFR.
- Clone
- 4D5-8
- Isotype
- IgG1 kappa
-
anti-ErbB2/Her2 (Trastuzumab Biosimilar) antibody
Reactivité: Humain FACS, ELISA, IHC Hôte: Lapin Monoclonal 4D5-8 unconjugated Recombinant Antibody
-
- Indications d'application
- Optimal working dilution should be determined by the investigator.
- Commentaires
-
NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar.
- Restrictions
- For Research Use only
-
- Buffer
- PBS with 0.02 % Proclin 300.
- Agent conservateur
- ProClin
- Précaution d'utilisation
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Stock
- 4 °C,-20 °C
- Stockage commentaire
- Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
-
-
: "Stapled EGFR peptide reduces inflammatory breast cancer and inhibits additional HER-driven models of cancer." dans: Journal of translational medicine, Vol. 17, Issue 1, pp. 201, (2020) (PubMed).
-
: "Stapled EGFR peptide reduces inflammatory breast cancer and inhibits additional HER-driven models of cancer." dans: Journal of translational medicine, Vol. 17, Issue 1, pp. 201, (2020) (PubMed).
-
- Antigène
- ErbB2/Her2 (Trastuzumab Biosimilar)
- Abstract
- ErbB2/Her2 (Trastuzumab Biosimilar) Produits
- Synonymes
- anticorps CD340, anticorps HER-2, anticorps HER-2/neu, anticorps HER2, anticorps MLN 19, anticorps NEU, anticorps NGL, anticorps TKR1, anticorps erb-b2 receptor tyrosine kinase 2, anticorps ERBB2
- Classe de substances
- Biosimilar
- Sujet
- CD340, Metastatic lymph node gene 19 protein (MLN 19), Proto-oncogene Neu, Proto-oncogene c-ErbB-2, Tyrosine kinase-type cell surface receptor HER2, p185erbB2, p185HER2, EGFR
- UniProt
- P04626
-
Vous êtes ici:
